Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.20 -5.5%	$1.39	$1.05 ▼ $10.16	$37.63M	1.56	253,022 shs	306,959 shs
ANCN Anchiano Therapeutics	$1.20 -1.6%	$21.77	$0.51 ▼ $10.55	$8.90M	0.93	3.15 million shs	72,258 shs
ITRM Iterum Therapeutics	$0.99 -0.9%	$1.04	$0.81 ▼ $3.02	$39.64M	2.78	1.05 million shs	459,255 shs
RVPH Reviva Pharmaceuticals	$0.73 -6.9%	$0.83	$0.49 ▼ $4.28	$33.95M	0.11	1.16 million shs	772,858 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	-5.51%	-11.11%	+5.26%	-77.94%	-84.11%
ANCN Anchiano Therapeutics	+1.44%	-7.58%	-3.17%	-13.48%	+22.01%
ITRM Iterum Therapeutics	-0.52%	+2.15%	+5.46%	-28.20%	-17.43%
RVPH Reviva Pharmaceuticals	-6.88%	-11.59%	-8.06%	-34.57%	-51.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	4.1271 of 5 stars	4.5	5.0	0.0	0.0	2.2	3.3	0.6
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	2.4201 of 5 stars	3.5	5.0	0.0	0.0	2.7	0.0	0.0
RVPH Reviva Pharmaceuticals	2.7245 of 5 stars	3.6	1.0	0.0	0.0	2.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,376.19% Upside
ANCN Anchiano Therapeutics	0.00	N/A	N/A	N/A
ITRM Iterum Therapeutics	3.00	Buy	$9.00	808.27% Upside
RVPH Reviva Pharmaceuticals	3.29	Buy	$9.00	1,139.16% Upside

Current Analyst Ratings Breakdown

Latest ANCN, ITRM, RVPH, and ACRV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/20/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $3.00
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/8/2025	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$9.00
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/24/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/1/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.00
3/26/2025	ACRV Acrivon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/26/2025	ACRV Acrivon Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.38 per share	N/A
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	$2.01 per share	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.12) per share	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$60.39M	-$2.22	N/A	N/A	N/A	N/A	-47.95%	-43.73%	8/12/2025 (Estimated)
ANCN Anchiano Therapeutics	-$27.12M	-$3.46	8.00	N/A	N/A	N/A	36.08%	27.40%	N/A
ITRM Iterum Therapeutics	-$24.77M	-$0.99	N/A	∞	N/A	N/A	N/A	-90.85%	8/13/2025 (Estimated)
RVPH Reviva Pharmaceuticals	-$39.26M	-$0.79	N/A	N/A	N/A	N/A	N/A	-252.53%	8/13/2025 (Estimated)

Latest ANCN, ITRM, RVPH, and ACRV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	RVPH Reviva Pharmaceuticals	-$0.21	-$0.13	+$0.08	-$0.13	N/A	N/A
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
5/13/2025	Q1 2025	ITRM Iterum Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A
3/31/2025	Q4 2024	RVPH Reviva Pharmaceuticals	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A
3/27/2025	Q4 2024	ACRV Acrivon Therapeutics	-$0.69	-$0.60	+$0.09	-$0.60	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	12.75	12.75
ANCN Anchiano Therapeutics	N/A	3.25	3.25
ITRM Iterum Therapeutics	N/A	1.41	1.41
RVPH Reviva Pharmaceuticals	N/A	0.39	0.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
ANCN Anchiano Therapeutics	9.05%
ITRM Iterum Therapeutics	9.21%
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
ANCN Anchiano Therapeutics	6.88%
ITRM Iterum Therapeutics	9.20%
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.36 million	28.49 million	Not Optionable
ANCN Anchiano Therapeutics	16	7.42 million	N/A	Not Optionable
ITRM Iterum Therapeutics	10	40.00 million	31.40 million	Not Optionable
RVPH Reviva Pharmaceuticals	5	46.74 million	24.35 million	Optionable

ANCN, ITRM, RVPH, and ACRV Headlines

Recent News About These Companies

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $9.00 Average Price Target from Brokerages

June 13 at 1:15 AM | americanbankingnews.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Pharmaceuticals' (RVPH) Buy Rating Reaffirmed at D. Boral Capital

June 5, 2025 | americanbankingnews.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.com

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | globenewswire.com

Reviva to Participate in the A.G.P. Healthcare Company Showcase

May 13, 2025 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)

May 4, 2025 | theglobeandmail.com

Reviva to Participate in the Citizens Life Sciences Conference

April 29, 2025 | finance.yahoo.com

RVPH: M&A Deals Highlight Brilaroxazine Value

April 7, 2025 | finance.yahoo.com

Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)

April 5, 2025 | markets.businessinsider.com

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

March 31, 2025 | markets.businessinsider.com

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

March 30, 2025 | globenewswire.com

Why Reviva Pharmaceuticals Holdings, Inc.’s (RVPH) Stock Is Down 10.61%

March 7, 2025 | aaii.com

Unusually active option classes on open February 12th

February 12, 2025 | markets.businessinsider.com

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 4, 2025 | globenewswire.com

Reviva to Participate in the 2025 BIO CEO & Investor Conference

January 30, 2025 | globenewswire.com

Reviva Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright

January 22, 2025 | markets.businessinsider.com

Reviva Pharmaceuticals Holdings Inc (RVPH) Stock Sees Market Value Hit $93.16 million: What Are the Implications?

January 22, 2025 | bovnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANCN, ITRM, RVPH, and ACRV Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.20 -0.07 (-5.51%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.22 +0.02 (+1.67%)

As of 06/13/2025 07:56 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Anchiano Therapeutics NASDAQ:ANCN

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Iterum Therapeutics NASDAQ:ITRM

$0.99 -0.01 (-0.91%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+0.92%)

As of 06/13/2025 07:41 PM Eastern

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.73 -0.05 (-6.88%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.75 +0.03 (+3.54%)

As of 06/13/2025 07:34 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time